The publications listed below present research results drawn from our clinical experience with whole body hyperthermia. You may also be interested in our laboratory research publications.

Bull JM, Scott G, Graham JL, Willis P, Dancsak T, Strebel FR, Oliver D, Redwine M, Koch SM
An Update of a Phase II Clinical Trial using Fever-Range Whole-Body Thermal Therapy (FR-WB-TT) + Cisplatin (CIS) + Gemcitabine (GEM) + Metronomic, Low-Dose Interferon-alpha (IFN-alpha) for Inoperable or Metastatic Pancreas Cancer
Abstract in Proceedings of the Society for Thermal Medicine 2006 Annual Meeting
Bethesda, MD, USA.

Bull JM, Scott G, Strebel FR, Oliver D, Raval B, Koch S
Update of a Phase I Clinical Trial using Fever-Range Whole-Body Hyperthermia (FR-WBH) + Cisplatin (CIS) + Gemcitabine (GEM) + Metronomic, Low-Dose Interferon-alpha (IFN-alpha)
Proceedings of the International Congress on Hyperthermic Oncology
20.-24.04.2004, St.Louis, USA. (Session 21 and Poster 689)

Scott G, Bull JM, Koch S
Management of Conscious Sedation for the Comfort and Control of PhysiologicaI/Hemodynamic Factors of Patients with Advanced and/or Metastatic Malignancies Undergoing Fever-Range Whole-Body Hyperthermia (FR- WBH) Thermo-Chemo-Bio-Therapy
Proceedings of the International Congress on Hyperthermic Oncology
20.-24.04.2004, St.Louis, USA. (Poster 899)

Pritchard MT, Ostberg JR, Evans SS, Burd R, Kraybill W, Bull JM, Repasky EA.
Protocols for simulating the thermal component of fever: preclinical and clinical experience.
Methods. 2004 Jan;32(1):54-62.

Bull JM, Nagle V, Scott G, Strebel FR, Sheridan, Koch S, Berry JM
A Phase I Study of optimally-timed GEM + CIS + IFN combined with long-duration, low-temperature WBH
Abstract in Proceedings of the European Society for Hyperthermic Oncology, May 2001, Verona, Italy

Berry JM, Michalsen A, Nagle V, Bull JM
The use of esmolol in whole-body hyperthermia: cardiovascular effects.
Int J Hyperthermia. 1997 May-Jun;13(3):261-8.

Nagle V, Berry JM, Bull JM
Gemcitabine HCL (Gemzar): A Heat Sensitive Drug for Synergistic Response ?
Proceedings of the 18th Annual Meeting of the North American Hyperthermia Soc. 1999 (Poster 13)

Nagle V, Berry JM, Bull JM
Cardiovascular Safety of Whole Body Hyperthermia (WBH) at 41.8°C and 40°C
Proceedings of the 18th Annual Meeting of the North American Hyperthermia Soc. 1999 (Poster 12)

Bull JM, Nagle V, Berry JM
Fever Range Hyperthermia and Pegylated Liposomal Doxorubicin in the Treatment of advanced Breast Cancer
Proceedings of the Congress of the American Society of Clinical Oncology 1998, Abstract 501

Nagle V, Berry JM, Bull JM
Initial Report of Febrile Range Whole Body Hyperthermia (LL-WBH) For Treatment of Advanced or Metastatic Cancer in Humans
Proceedings of the 17th Annual Meeting of the North American Hyperthermia Society, 1998 (P01-4)

Bull JM, Cronau LH, Newman BM, Jabboury K, Allen SJ, Ohno S, Smith T, Tonnesen AS
Chemotherapy resistant sarcoma treated with whole body hyperthermia (WBH) combined with 1-3-bis(2-chloroethyl)-1-nitrosourea (BCNU).
Int J Hyperthermia. 1992 May-Jun;8(3):297-304.

Tonnesen AS, Marnock C, Bull JM, Morgenweck CJ, Fallon KD
Sweating, hemodynamic responses, and thermal equilibration during hyperthermia in humans.
J Appl Physiol. 1987 Apr;62(4):1596-602.

Strother SV, Bull JM, Branham SA
Activation of coagulation during therapeutic whole body hyperthermia.
Thromb Res. 1986 Aug 1;43(3):353-60.

Cronau LH Jr, Bourke DL, Bull JM
General anesthesia for whole-body hyperthermia.
Cancer Research. 1984 Oct;44(10 Suppl):4873s-4877s.

Bull JM
A review of systemic hyperthermia.
Front Radiat Ther Oncol. 1984;18:171-6. Review.

Bull JM, Lees DE, Schuette WH, Smith R, Glatstein E, DeVita VT Jr
Immunological and physiological responses to whole-body hyperthermia.
Natl Cancer Inst Monogr. 1982 Jun;61:177-81.